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Specific ligands of the peripheral benzodiazepine receptor (PBR) are known to induce apoptosis and cell cycle arrest in oesophageal
cancer cells. However, the underlying mechanisms are still unknown. Here, we investigated the transcriptional alterations and
activation of protein kinases in response to PBR-specific ligands. Using cDNA arrays, we examined the transcriptional effects of the
PBR-specific ligand FGIN-1-27 in two oesophageal cancer cell lines, KYSE-140 (squamous cell carcinoma) and OE-33
(adenocarcinoma). In oesophageal cancer cells, FGIN-1-27 induced extensive changes in the expression of genes involved in the
regulation of apoptosis and cell cycle. Both in oesophageal cancer cell lines (KYSE-140, OE-33) we observed a strong upregulation of
the growth arrest and DNA-damage-inducible genes, gadd45 and gadd153, in response to PBR ligands. gadd genes are known to be
induced by p38MAPK activation. Using Western blotting we detected a time- and dose-dependent phosphorylation of p38MAPK,
which was found to be functionally involved in gadd induction, apoptosis, and cell cycle arrest. In conclusion, our data indicate that
PBR-specific ligands cause apoptosis and cell cycle arrest by activation of the p38MAPK pathway and induction of gadd45 and
gadd153.
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Originally, the peripheral benzodiazepine receptor (PBR) was
described as another class of binding sites for benzodiazepines
distinct from the central benzodiazepine receptor (CBR) (Braestr-
up and Squires, 1977). It was identified as a mitochondrial 18kDa
protein (McEnery et al, 1992). In contrast to CBR, PBR exhibits
high affinity for the isoquinoline carboxamide PK 11195 and the
indoleacetamide FGIN-1-27 (Kozikowski et al, 1993). Conversely,
clonazepam binds with high affinity to CBR, but has extremely low
affinity for PBR (Wang et al, 1984b). In the outer mitochondrial
membrane, PBR is associated with the voltage-dependent anion
channel and the adenine nucleotide translocator, all of which
contribute to the formation of the mitochondrial permeability
transition pore (McEnery et al, 1992).
Although present in all tissues to some extent, PBR is highly
expressed in steroid-producing tissues (Beurdeley-Thomas et al,
2000). Besides its well-established function in the regulation of
steroidogenesis (Papadopoulos et al, 1997), the abundance of PBR
in cancers of the colon (Katz et al, 1990b; Maaser et al, 2002a),
brain (Cornu et al, 1992), breast (Hardwick et al, 1999), ovary
(Katz et al, 1990a), and liver (Venturini et al, 1998) suggests an
additional role in tumorigenesis. The proliferation of breast cancer
(Beinlich et al, 1999; Carmel et al, 1999), melanoma (Landau et al,
1998), Leydig’s cell tumour (Garnier et al, 1993), astrocytoma
(Neary et al, 1995), colorectal (Maaser et al, 2001), and
oesophageal carcinoma (Sutter et al, 2002) was shown to be
inhibited by PBR-specific ligands. In haematopoetic and epithelial
cells, the antiproliferative effects of PBR-specific ligands were
mediated by the induction of apoptosis and cell cycle arrest
(Tanimoto et al, 1999; Maaser et al, 2001; Sutter et al, 2002).
However, the underlying mechanisms of PBR-ligand-mediated
apoptosis are far from being understood. Several reports have been
published on the potential mechanisms contributing to PBR-
ligand-mediated apoptosis. Recently, we have shown that mito-
chondrial membrane permeabilisation is a necessary and early step
in PBR-ligand-mediated apoptosis of oesophageal cancer cells
(Sutter et al, 2002). In other cell types, a mitochondria-dependent
mechanism has been suggested (Fischer et al, 2001; Maaser et al,
2001). Additionally, PBR-ligand-induced apoptosis of thymocytes
was found to be sensitive to actinomycin D, cycloheximide, and the
protein kinase inhibitor H7, suggesting a requirement for protein
synthesis and phosphorylation (Tanimoto et al, 1999). Down-
regulation of Bcl-2 expression and dephosphorylation of protein
kinase B and Bad were shown to be associated with PBR-ligand-
induced apoptosis of hepatic stellate cells (Fischer et al, 2001).
However, little is known about other transcriptional responses to
treatment with PBR-specific ligands.
Cell cycle regulators are frequently disabled in human cancer.
Hence, the modulation of cell cycle regulation is a feasible strategy
for treating cancer (Shapiro and Harper, 1999). The induction of
cell cycle arrest is a well-studied property of PBR-specific ligands.
In oesophageal cancer cells, PBR-specific ligands induce a tumour-
selective growth arrest at the G1/S checkpoint (Sutter et al, 2002). Received 24 January 2003; revised 30 April 2003; accepted 7 May 2003
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ectal cancer cells (Maaser et al, 2001). Additionally, PBR ligands
induce a cell cycle arrest at both major restriction points, the G1/S-
and the G2/M junction (Carmel et al, 1999; Sa ¨nger et al, 2000) in
breast cancer cells, whereas in lung and melanoma cells an
accumulation is observed in the G2/M phase (Landau et al, 1998).
However, the exact mechanism of PBR-ligand-mediated cell cycle
arrest is not yet understood.
Employing cDNA arrays and RT–PCR, we assessed the PBR-
ligand-induced downstream transcriptional profiles in oesopha-
geal cancer cells. Here, we report on p38MAPK activation and gadd
overexpression in response to PBR-specific ligands, leading to
apoptosis and cell cycle arrest.
MATERIAL AND METHODS
Cell lines and drugs
The human oesophageal squamous carcinoma cell line KYSE-140
(Shimada et al, 1992) and the human colorectal adenocarcinoma
cell line HT-29 were grown in RPMI 1640 medium supplemented
with 10% FBS. The human oesophageal adenocarcinoma cell line
OE-33 (Rockett et al, 1997) was grown in RPMI 1640 medium
supplemented with 10% FBS and 2mML-glutamine. Cell lines were
cultured in a humidified atmosphere (5% CO2)a t3 7 1C. To
evaluate the effects of PBR-specific ligands, cells were incubated
with either control medium or medium containing FGIN-1-27, PK
11195 (Tocris, Bristol, UK), clonazepam (Sigma, Deisenhofen,
Germany), or FGIN-1-52 (Kozikowski et al, 1993). SB202190
(2–20mM, Calbiochem-Novabiochem, Bad Soden, Germany) was
used for p38MAPK inhibition. DEVD-CHO (10mgml
 1, Calbio-
chem-Novabiochem, Bad Soden, Germany) was used for caspase-3
inhibition.
RNA extraction and polyA
þ mRNA preparation
Total RNA was extracted from cultured cell lines with RNAClean
following the recommendation of the manufacturer (Hybaid,
London, UK). Polyadenylated (polyA
þ) mRNAs were enriched
using magnetic Dynabeads according to the instructions of the
supplier (Dynal, Oslo, Norway). The quality of polyA
þ and total
RNA was controlled by agarose gel electrophoresis.
cDNA array
KYSE-140 and OE-33 cells were treated with FGIN-1-27 (50mM) for
24h to determine PBR-ligand-induced differential gene expression.
Untreated cells served as controls. We used an Atlas Human
Apoptosis cDNA array with 205 human cDNAs spotted in
duplicate on a nylon membrane (Clontech, Palo Alto, CA, USA).
A complete list of the cDNAs and controls as well as their accession
numbers is available on the web (http://atlasinfo.clontech.com/
genelists/huApop.xls). The membranes were hybridised with
labelled cDNA probes prepared by reverse transcription from
1mg polyA
þ mRNA using the respective protocol from Clontech.
Probes used for hybridisation were equalised to a radioactivity of
2 10
6cpmml
 1 hybridisation solution. Overnight incubation was
followed by stringent washing as recommended by the manufac-
turer. The membranes were then exposed to X-ray film for
quantification. The hybridisation signals were photometrically
evaluated using TINA software (raytest Isotopenmessgera ¨te,
Straubenhardt, Germany).
cDNA array data analysis
Alteration in the expression of a respective gene is given as fold
increase/or decrease compared to the signal of the untreated control
(Ho ¨pfner et al, 2002). For determining up- and downregulation, the
mean optical density  mm
 2 (OD  mm
 2) of each gene was
identified and normalised to the expression of different house-
keeping genes (ubiquitin, glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH), tubulin a 1 subunit, HLA class I histocompatibility
antigen C-4 a subunit (HLAC), cytoplasmic b-actin, 60S ribosomal
protein L13A, 40S ribosomal protein S9). Then the ratio of gene
expression in treated vs untreated cells was calculated. Data were
used only when both signals were 50% or more above background,
and if the deviations between duplicates did not exceed the
difference between treated and untreated conditions. Each hybri-
disation experiment was repeated three times.
Semiquantitative RT–PCR
Semiquantitative analysis of mRNA expression of the genes coding
for gadd45, gadd153, and for the housekeeping gene b-actin was
carried out by RT–PCR with the number of cycles at which the
band intensity increased linearly with the amount of mRNA used.
For RT–PCR, 2mg of total RNA was digested with 1U DNAse I
(Gibco, Karlsruhe, Germany) for 15min at room temperature.
Oligo-dT-primers and the SuperScript Preamplification-Kit (Gib-
co, Karlsruhe, Germany) were used for cDNA synthesis. PCR
reactions were carried out in a total volume of 50ml containing
400nM of each primer, 200mM of each dNTP (Pharmacia, Uppsala,
Sweden), 50mM KCl, 1.5mM MgCl2,1 0 m M Tris, and 1U Taq-
Polymerase (Pharmacia, Uppsala, Sweden). PCR was performed in
a Peltier thermocycler (PTC-200, MJ-Research, USA) with the
primers and at the conditions indicated in Table 1 (Oh-Hashi et al,
2001).
Western blotting
Whole-cell extracts were prepared by harvesting and lysing the
cells with lysis buffer (SDS 0.1%, sodium deoxycholic acid 0.5%,
Nonidet P-40 1%, PMSF 0.1mM, aprotinin 1mgml
 1, pepstatin A
1mgml
 1). The protein content of the lysate was determined using
Table 1 Primer sequences and PCR conditions used to evaluate the expression of the transcripts indicated
Genes Primers (50–30)
Position in the
mRNA
Product size
(bp)
Denaturing
temperature
and time (s)
Annealing
temperature
and time (s)
Extension
temperature
and time (s)
Number
of cycles
gadd45 F: AGAACGACATCAACATCCTGC 534–554 144 951C (30) 601C (30) 721C (60) 35
R: AATGTGGATTCGTCACCAGCA 657–677
gadd153 F: AACCAGCAGAGGTCACAAGC 377–396 217 951C (30) 601C (30) 721C (60) 33
R: AGCCGTTCATTCTCTTCAGC 574–593
b-actin F: ATCATGTTTGAGACCTTCAACAC 437–459 822 941C (40) 631C (60) 721C (60) 29
R: TCTGCGCAAGTTAGGTTTTGTC 1237–1258
All templates were initially denatured for 5min at 951C and the amplicon was extended at a final extension temperature of 721C for 7min.
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lysate was mixed with gel loading buffer (Tris-HCl 62.5mM,
glycerol 10%, SDS 1%, b-mercaptoethanol 2.5%). After boiling for
5min, the lysates were subjected to SDS–polyacrylamide gel
electrophoresis (20mg of protein per lane; gel: polyacrylamide 12%,
SDS 0.1%, Tris-HCl 25mM; running buffer: Tris 25mM, glycine
50mM, 0.1% SDS). After electrophoresis, gels were equilibrated
with transfer buffer (Tris 25mM, glycine 50mM, 20% methanol).
Proteins were transferred to PVDF membranes by electroblotting.
Blots were blocked in 1.5% BSA, and then incubated at 41C
overnight with anti-human p38MAPK or phospho-p38MAPK
(1:500, Santa Cruz Biotechnology, CA, USA). After washing with
PBS containing 0.1% Tween and incubation with horseradish
peroxidase-coupled anti-IgG antibody (1:10000, Amersham,
Uppsala, Sweden) at room temperature for 1h, the blot was
washed extensively and developed using enhanced chemilumines-
cent detection (Amersham, Uppsala, Sweden). Blots were exposed
to Hyperfilm ECL film (Amersham, Uppsala, Sweden) for
1–30min and analysed densitometrically using TINA software
(raytest Isotopenmessgera ¨te, Straubenhardt, Germany).
Caspase-3 activity assay
To determine caspase-3 activity, cells were washed twice with PBS
and stored at  801C until use. Cells (10
6) were lysed with lysis
buffer (Tris-HCl 10mM, NaH2PO4/Na2HPO4 10mM, NaCl 130mM,
Triton X-100 1%, NaPPi 10mM, pH 7.5), and the total protein
content was quantified using the BCA protein assay kit (Pierce,
Rockford, IL, USA). The activity of caspase-3 was calculated from
the cleavage of the fluorogenic substrate DEVD-AMC (Calbio-
chem-Novabiochem, Bad Soden, Germany). In brief, cell lysates
were incubated with substrate solution (caspase-3 substrate AC-
DEVD-AMC 20mgml
 1, HEPES 20mM, glycerol 10%, DTT 2mM,
pH 7.5) for 1h at 371C. The cleavage of DEVD-AMC was measured
with a VersaFluor fluorometer (excitation: 360nm emission:
460nm) from Biorad, Munich, Germany (Maaser et al, 2002b).
DNA fragmentation
DNA fragmentation was determined by Cell Death Detection
ELISA (Roche Molecular Biochemicals) according to the manu-
facturer’s instructions (Ho ¨pfner et al, 2003). Briefly, after
incubation with the indicated compounds, cells were lysed in
incubation buffer. The cytoplasmic fractions were diluted to
contain 2.5 10
3cell equivalents per ml, and presence of mono-
and oligonucleosomes was tested using antibodies directed against
DNA and histones. DNA fragments were detected by a peroxidase
system, with colour development analysed at 405nm by an ELISA
reader.
Cell cycle analysis
Cell cycle analysis was performed by the method of Vindelov and
Christensen (1990). Cells were trypsinised, washed, and the nuclei
were isolated using CycleTest PLUS DNA Reagent Kit (Becton
Dickinson, Heidelberg, Germany). DNA was stained with propi-
dium iodide according to the manufacturer’s instructions. The
DNA content of the nuclei was detected by flow cytometry and
analysed using CellFit software (Becton Dickinson, Heidelberg,
Germany).
Statistical analysis
Individual drug therapy was compared by the unpaired, two-tailed
Mann–Whitney U-test. The unpaired Student’s t-test was used for
cell cycle analysis. P-values were considered to be significant at
o0.05. If not stated otherwise, all experiments were performed
in quadruplicate.
RESULTS
Peripheral benzodiazepine receptor-ligand-induced
differential gene expression
Peripheral benzodiazepine receptor-specific ligands have been
shown to induce apoptosis and cell cycle arrest potently in human
oesophageal cancer cells (Sutter et al, 2002). We used cDNA arrays
to analyse changes in the expression of apoptosis- and cell cycle-
regulating genes elicited by PBR-specific ligands (Ho ¨pfner et al,
2002). For cDNA array experiments, we chose a concentration of
50mM FGIN-1-27 and a 24-h incubation time, which is sufficient to
induce apoptosis and cell cycle arrest (Maaser et al, 2001; Sutter
et al, 2002).
We found over 45 genes that were differentially expressed in
both KYSE-140 and OE-33 cells. FGIN-1-27 treatment resulted in
an asymmetric distribution of overexpressed vs suppressed genes.
Moreover, a comparison of the up- and downregulated genes
revealed discrepancies in the FGIN-1-27-induced regulation
between the two cell lines: in KYSE-140 (12 overexpressed, 35
suppressed), 25.5% of the regulated genes were overexpressed and
74.5% were suppressed. In contrast, 65.2% of the genes were
overexpressed and 34.8% were suppressed in OE-33 cells (30
overexpressed, 16 suppressed). Tables 2 and 3 show the genes
regulated by FGIN-1-27 in KYSE-140 and OE-33 cells, respectively.
Tanimoto et al (1999) have demonstrated that PBR-ligand-
induced apoptosis required protein de novo synthesis. Therefore,
we focused on the genes being overexpressed in both the cancer
cell lines. In KYSE-140, five genes were induced by FGIN-1-27 to a
level exceeding the expression ratio of 2.0. Three of these genes
(gadd153, gadd45, and factor associated with neutral sphingomye-
linase activation) were also induced in OE-33 cells, suggesting that
these genes are involved in a common signalling pathway. gadd45
and gadd153, both of which are activated by p38MAPK (Kultz et al,
1998), have been associated with apoptosis and growth arrest
induced by various extracellular stimuli (Kultz et al, 1998; Maytin
et al, 2001; Oh-Hashi et al, 2001). These two genes were selected for
further analysis.
Peripheral benzodiazepine receptor-specific ligands induce
gadd45 and gadd153 mRNA expression
Semiquantitative RT–PCR analysis was performed to confirm the
overexpression of gadd45 and gadd153 observed by cDNA array
analysis and to monitor their temporal induction. FGIN-1-27 and
PK 11195 induced gadd45 and gadd153 rapidly after 2–4h of
treatment, with maximal expression of both transcripts occurring
after 8–24h for FGIN-1-27 and after 4–6h for PK 11195. The
kinetics of induction, however, differed for the two ligands: during
treatment with PK 11195, both transcripts returned to basal level
after 8h, but remained elevated up to 24h after treatment with
FGIN-1-27 (Figure 1A, B). To study if gadd overexpression
commonly occurred in response to PBR activation, we also
analysed gadd expression in FGIN-1-27- or PK 11195-treated
HT-29 colorectal cancer cells. HT-29 cells have previously
been characterised regarding PBR expression and PBR-ligand-
induced apoptosis (Maaser et al, 2001). Both FGIN-1-27
and PK 11195 induced a transient overexpression of gadd153,
reaching a maximal induction after 24h (50mM FGIN-1-27,
ratio¼7.073.2) or 6h (50mM PK 11195, ratio¼3.370.4). Similar
to the findings in oesophageal cancer cells, gadd45 was also
overexpressed in HT-29 cells after a 24-h incubation with PBR
ligands (data not shown).
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induction
Mitogen-activated protein (MAP) kinases represent one of the
most important signalling cascades in response to extracellular
stimuli (Chan-Hui and Weaver, 1998). To gain an insight into the
PBR-ligand-mediated signal transduction pathways responsible for
gadd45 and gadd153 induction, we determined the influence of the
p38MAPK (stress-activated protein kinase 2) cascade. We used the
potent p38MAPK inhibitor SB202190 (Herlaar and Brown, 1999;
Lee et al, 2000; Mayr et al, 2002) to determine whether p38MAPK
activation is directly associated with the induction of gadd
messages in oesophageal cancer cells. SB202190 belongs to a
family of pyridinyl imidazole compounds that have been shown to
inhibit specifically p38MAPkinase activity at the concentrations
used, but do not exhibit any significant effect upon a variety of
other kinases such as JNK, ERK-1, and MAPKAP kinase 2 (Lee
et al, 1994; Cuenda et al, 1995). The FGIN-1-27-mediated induction
of gadd45 and gadd153 transcripts was markedly decreased after
preincubating the cells with SB202190 for 1h (Figure 1C).
SB202190 alone had no effect on gadd expression (data not
shown). These data suggest that p38MAPK activation contributes
to the induction of gadd45 and gadd153 by the PBR-specific ligand
FGIN-1-27.
p38MAPK activation by PBR-specific ligands
Phosphorylation-mediated activation of the p38MAPK by PBR-
specific ligands was determined by Western blotting. Both PBR-
specific ligands, FGIN-1-27 and PK 11195, induced a time- and
dose-dependent phosphorylation of p38MAPK, thereby showing
high correlation with the induction of gadd transcripts (Figure 2A,
B). The maximum of p38MAPK activation was observed after 4h
(FGIN-1-27) or 1–8h (PK 11195) of treatment. After 4h, we
observed an about 1.7-fold activation of p38MAPK in response to
10mM of the respective PBR ligand and an about 3.1-fold activation
Table 2 Transcripts differentially regulated in KYSE-140 in response to FGIN-1-27
GenBank ID Gene name Mean
a s.d.
S40706 gadd153 7.24 2.73
X96586 FAN protein 3.70 0.07
X07282 Retinoic acid receptor, b 2.63 0.82
X08020 Glutathione S-transferase M4 2.49 0.98
M60974 gadd45 2.27 0.88
U34051 Cyclin-dependent kinase 5 1.88 0.30
L26318 Mitogen-activated protein kinase 8, JNK1 1.63 0.04
U76376 Harakiri. BCL2-interacting protein 1.59 0.13
L29220 CDC-like kinase 3 1.57 0.42
X15480 Glutathione S-transferase pi 1.46 0.07
U11791 Cyclin H 1.45 0.21
M84820 Retinoid X receptor, beta 1.23 0.17
M25627 Glutathione S-transferase A2 0.82 0.15
X03484 v-raf-1 murine leukaemia viral oncogene homolog 1 0.78 0.11
Y00285 Insulin-like growth factor 2 receptor 0.77 0.08
M62402 Insulin-like growth factor binding protein 6 0.77 0.13
L35253 Mitogen-activated protein kinase 14, p38MAPK 0.76 0.13
U37448 Caspase 7 0.75 0.01
S90469 P450 (cytochrome) oxidoreductase 0.75 0.03
D13639 Cyclin D2 0.74 0.10
AF016268 Tumour necrosis factor receptor superfamily, member 10b 0.74 0.10
M34065 Cell division cycle 25C 0.73 0.08
L16785 NM23B 0.73 0.17
X89986 BCL2-interacting killer (apoptosis-inducing) 0.71 0.12
U66879 BCL2-antagonist of cell death 0.71 0.06
U21092 TNF receptor-associated factor 3 0.66 0.11
U01038 Polo (Drosophia)-like kinase 0.65 0.16
X60188 Mitogen-activated protein kinase 3, ERK1 0.65 0.18
Y11416 Tumour protein p73 0.65 0.25
U34819 Mitogen-activated protein kinase 10, JNK3 0.64 0.03
L41690 TNFRSF1A-associated via death domain 0.64 0.28
AF015956 Death-associated protein 6 0.63 0.31
AF022385 Programmed cell death 10 0.62 0.15
U49070 Protein (peptidyl-proly|cis/trans isomerase) NIMA-interacting 1 0.61 0.07
M84489 Mitogen-activated protein kinase 1, ERK2 0.58 0.06
X86779 Fas-activated serine/threonine kinase 0.58 0.17
U60520 Caspase 8 0.57 0.23
U90313 Glutathione transferase omega 0.56 0.16
M35410 Insulin-like growth factor binding protein 2 0.56 0.06
L22474 BCL2-associated X protein 0.55 0.15
U38545 Phospholipase D1 0.54 0.05
U10564 Wee1+ (S. pombe) homologue 0.49 0.13
D89667 Prefoldin 5 0.49 0.22
U82938 CD27-binding (Siva) protein 0.48 0.03
M74091 G1/S-specific cyclin C 0.44 0.22
M15796 Proliferating cell nuclear antigen 0.44 0.33
D38122 Tumour necrosis factor (ligand) superfamily, member 6 0.18 0.01
aArithmetic means of ratios (treated: untreated) from three separate array measurements
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to 4.1-fold increase of activated p38MAPK. As activation was
pronounced at 50mM of either ligand already, we chose this
concentration for further experiments. PBR-specific ligands did
not affect the expression of either p38MAPK protein (Figure 2) or
mRNA (data not shown) analysed within a period of 24h.
FGIN-1-27-induced caspase-3 activation contributes to
activation of p38MAPK
Peripheral benzodiazepine receptor-ligand-mediated apoptosis
involves caspase-3 activation, leading to DNA fragmentation and
cell death (Sutter et al, 2002). The PBR-specific ligand FGIN-1-27
induced a dose- (Sutter et al, 2002) and time-dependent increase in
caspase-3 activity in both KYSE-140 (Figure 3A) and OE-33
(Figure 3B) cells. The time course of PBR-ligand-induced caspase-3
activation correlates with p38MAPK phosphorylation, suggesting a
link between caspase-3 and p38MAPK activation. Thus, a possible
regulatory relationship between caspase-3 and p38MAPK during
PBR-ligand-mediated apoptosis was investigated. KYSE-140 cells
were treated with FGIN-1-27 (50mM) for 4h in the presence or
absence of the caspase-3 inhibitor DEVD-CHO (10mgml
 1). This
concentration was previously shown to be sufficient to inhibit
caspase-3 activation and DNA fragmentation (Sutter et al, 2002).
Cells pretreated with DEVD-CHO displayed a markedly ( 42%)
reduced activation of p38MAPK (Figure 2C), indicating that in
FGIN-1-27-induced apoptosis of KYSE-140 cells, caspase-3 activa-
tion contributes to p38MAPK activation. On the other hand,
pretreatment of KYSE-140 cells with SB202190 did not prevent
caspase-3 activation by FGIN-1-27, even at the highest concentra-
tion of the p38MAPK inhibitor, demonstrating that p38MAPK
activation is not required for caspase-3 activation (data not
shown).
FGIN-1-27-induced p38MAPK activation contributes to
DNA fragmentation
Finally, we investigated if p38MAPK activation contributes to
FGIN-1-27-induced DNA fragmentation. Thus, KYSE-140 cells
were treated with FGIN-1-27 (50mM) either in the presence or in
Table 3 Transcripts differentially regulated in OE-33 in response to FGIN-1-27
GenBank ID Gene name Mean
a s.d.
S40706 gadd153 2.76 0.82
X60188 Mitogen-activated protein kinase 3, ERK1 2.02 0.45
U90313 Glutathione transferase omega 1.94 0.86
L27211 Cyclin-dependent kinase inhibitor 2A 1.92 0.68
X59798 Cyclin D1 1.91 0.77
M81934 Cell division cycle 25B 1.88 0.39
M31159 Insulin-like growth factor binding protein 3 1.87 0.62
U34051 Cyclin-dependent kinase 5 1.83 0.37
M63167 v-akt murine thymoma viral oncogene homolog 1 1.83 0.36
U28014 Caspase 4 1.82 0.31
U63131 Cell division cycle 37 1.74 0.46
Y00285 Insulin-like growth factor 2 receptor 1.69 0.05
S78085 Programmed cell death 2 1.68 0.04
M34065 Cell division cycle 25C 1.67 0.63
AF010312 LPS-induced TNF-alpha factor 1.67 0.21
L05624 Mitogen-activated protein kinase kinase 1, MEK1 1.62 0.45
L41690 TNFRSF1A-associated via death domain 1.59 0.37
M14505 Cyclin-dependent kinase 4 1.57 0.35
L29511 Growth factor receptor-bound protein 2 1.56 0.38
D89667 Prefoldin 5 1.54 0.25
U82938 CD27-binding (Siva) protein 1.54 0.50
L29216 CDC-like kinase 2 1.53 0.43
M15796 Proliferating cell nuclear antigen 1.48 0.32
M84820 Retinoid X receptor, beta 1.48 0.31
X96586 FAN protein 1.44 0.23
L22005 Cell division cycle 34 1.40 0.18
U13737 Caspase 3 1.38 0.26
M60974 gadd45 1.37 0.00
X92669 Menage a trois 1 (CAK assembly factor) 1.33 0.05
M81933 Cell division cycle 25A 1.23 0.11
M29645 Insulin-like growth factor 2 (somatomedin A) 0.89 0.05
X01394 Tumour necrosis factor (TNF superfamily, member 2) 0.83 0.03
X15480 Glutathione S-transferase pi 0.77 0.05
L07414 Tumour necrosis factor (ligand) superfamily, member 5 0.75 0.19
U69108 TNF receptor-associated factor 5 0.72 0.05
D12614 Lymphotoxin alpha (TNF superfamily, member 1) 0.72 0.12
U33286 Chromosome segregation 1 (yeast homologue)-like 0.70 0.04
U78798 TNF receptor-associated factor 6 0.67 0.04
L08246 Myeloid cell leukaemia sequence 1 (BCL2-related) 0.62 0.10
M73812 Cyclin E1 0.61 0.16
U56390 Caspase 9 0.59 0.19
U60520 caspase 8 0.55 0.34
L31951 Mitogen-activated protein kinase 9, JNK2 0.48 0.50
X05360 Cell division cycle 2 0.44 0.07
U75285 Survivin 0.43 0.25
M32315 Tumour necrosis factor receptor superfamily, member 1B 0.41 0.31
aArithmetic means of ratios (treated:untreated) from three separate array measurements
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ythe absence of SB202190. Cells pretreated with SB202190 for 1h
displayed a reduced DNA fragmentation, providing evidence that
p38MAPK activation is involved in DNA fragmentation
(Figure 4A).
Activation of the p38MAPK pathway is responsible for
FGIN-1-27-mediated cell cycle arrest
Peripheral benzodiazepine receptor ligands have been shown to
arrest the cell cycle of human oesophageal cancer cells in the
G0/G1 phase, thereby causing a G1/S arrest (Sutter et al, 2002).
Thus, we analysed whether p38MAPK activation was involved in
PBR-ligand-mediated cell cycle arrest. Preincubating KYSE-140
cells with SB202190 completely abolished FGIN-1-27-induced G1/S
arrest in oesophageal cancer cells (Figure 4B), suggesting that
p38MAPK activation is required for the cell cycle arrest observed.
SB202190 alone did not have any significant impact on the cell
cycle.
DISCUSSION
In this study we provide an insight into the signal transduction
pathway by which PBR-specific ligands induce cell cycle arrest and
apoptosis in oesophageal cancer cells. Peripheral benzodiazepine
receptor-specific ligands activate the p38MAPK signalling path-
way, leading to overexpression of gadd45 and gadd153 and cell
cycle arrest. Furthermore, we show that PBR-ligand-induced
caspase-3 activation contributes to p38MAPK activation, resulting
in DNA fragmentation. This suggests an involvement of p38MAPK
in PBR-mediated apoptosis.
The p38MAPK pathway is known to be activated by a variety of
stimuli including UV irradiation, hydrogen peroxide, DNA
damage, heat, and hyperosmotic shock. Activation of the
p38MAPK pathway results in growth arrest and apoptosis (Kultz
et al, 1998; Ichijo, 1999). We used the pyridinyl imidazole inhibitor
SB202190 to demonstrate the involvement of p38MAPK in PBR-
ligand-mediated apoptosis and cell cycle arrest. SB202190 has been
shown to inhibit p38MAPK a and b at the concentrations applied,
whereas it shows no effect against a large panel of other related
protein kinases tested (Davies et al, 2000). SB202190 has widely
been used to study the involvement of p38MAPK in proliferation,
apoptosis, and differentiation (Kultz et al, 1998; Oh-Hashi et al,
2001). In this study, SB202190 prevented PBR-ligand-induced
apoptosis and G1/S arrest, suggesting an involvement of the
p38MAPK pathway.
Mitogen-activated protein kinase (MAPK) signal transduction
pathways are known to regulate the expression of the gadd genes
(Kultz et al, 1998; Oh-Hashi et al, 2001). Thus, our next goal was to
elucidate if p38MAPK is involved in PBR-ligand-mediated gadd
overexpression. The expression of the gadd45 gene has been
correlated with the presence of strong growth arrest (Zhan et al,
1994a), and it has been shown to associate with proliferating cell
nuclear antigen (PCNA), where it may play a role in DNA repair
(Smith et al, 1994). Overexpression of each gadd gene causes
growth inhibition and/or apoptosis, and combined overexpression
of the gadd genes leads to a synergistic suppression of cell growth
(Zhan et al, 1994b). In this study, inhibition of p38MAPK activity
by SB202190 suppressed the expression of gadd genes induced by
PBR-specific ligands. These results confirm earlier findings that
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Figure 1 mRNA expression of gadd45 and gadd153 in response to
PBR-ligands: involvement of the p38MAPK signalling pathway. mRNA
expression of gadd45 and gadd153 in KYSE-140 cells (A) or OE-33 cells
(B) was detected after incubation with FGIN-1-27 or PK 11195. (C)
mRNA expression of gadd45 and gadd153 in KYSE-140 cells treated with
FGIN-1-27 for 8h in the presence or absence of SB202190. Pretreatment
with SB202190 markedly reduced gadd induction elicited by FGIN-1-27.
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Figure 2 Activation of p38MAPK by PBR-specific ligands: involvement of
caspase-3. Posphorylation of p38MAPK was analysed by Western blotting
using antibodies against the active form (P-p38MAPK) and nonpho-
sphorylated p38MAPK. p38MAPK was transiently phosphorylated in KYSE-
140 (A) and OE-33 cells (B) by FGIN-1-27 or PK 11195. (C) p38MAPK
phosphorylation in KYSE-140 cells treated with either vehicle, FGIN-1-27
(4h), or DEVD-CHO for 1h followed by FGIN-1-27 for 4h. Pretreatment
with DEVD-CHO attenuated FGIN-1-27-induced p38MAPK phosphoryla-
tion.
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ygadd induction occurs as a direct consequence of p38MAPK
activation (Oh-Hashi et al, 2001). The potency of SB202190 to
inhibit gadd45 and gadd153 overexpression correlated well with its
ability to decrease apoptosis and cell cycle arrest, suggesting an
involvement of gadd genes in apoptosis and G1/S arrest. In
accordance with our findings, it has been reported that G1/S arrest
is a result of gadd induction by p38MAPK (Smith et al, 1994).
However, as even the highest concentration of SB202190 only
partially prevented the increase in gadd45 and gadd153 expression,
other still unidentified, p38MAPK-independent pathways (Maytin
et al, 2001) may contribute to PBR-ligand-mediated gadd
induction: the generation of reactive oxygen species, the activation
of the p53 pathway or the JNK pathway are well known to induce
gadd genes, too (Guyton et al, 1996; Sheikh et al, 2000). In our
previous report on PBR-ligand-mediated apoptosis of oesophageal
cancer cells, we showed that disruption of the mitochondrial
membrane potential was required for caspase-3 activation (Sutter
et al, 2002). Using the caspase-3-specific inhibitor DEVD-CHO, we
now demonstrate that caspase activation is upstream of p38MAPK
activation, supporting previous findings in Jurkat T lymphocytes
(Juo et al, 1997, 1998; Matsuda et al, 1999). Interestingly, caspase-3
activation occurs independently of p38MAPK, as the p38MAPK
inhibitor SB202190 failed to prevent the activation of caspase-3.
Furthermore, FGIN-1-27-induced DNA fragmentation is decreased
by pretreatment with SB202190, suggesting an involvement of
p38MAPK in PBR-ligand-mediated formation of oligonucleo-
somes.
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Figure 3 PBR-ligand-induced caspase-3 activation. KYSE-140 (A) or OE-
33 cells (B) were treated with FGIN-1-27 (50 mM). Caspase-3 activity was
measured fluorometrically by the cleavage of DEVD-AMC. Data are given
as percentage of untreated control (means7s.e.m. of four independent
experiments).
* Statistical significance (Po0.05) compared to untreated
control.
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Figure 4 p38MAPK activation is required for FGIN-1-27-mediated DNA
fragmentation and G1/S arrest. (A) KYSE-140 cells, incubated with 50mM
FGIN-1-27 alone or in combination with SB202190, were analysed for
DNA fragmentation. Cells were preincubated for 1h with SB202190 prior
to FGIN-1-27 addition and subsequent incubation for 14h. Untreated cells
(ctrl), and cells treated only with SB202190, were also run as controls.
SB202190 strongly diminished FGIN-1-27-induced DNA fragmentation.
(B) KYSE-140 cells were treated with either vehicle, FGIN-1-27 for 24h,
SB202190 for 25h, or SB202190 for 1h followed by FGIN-1-27 plus
SB202190 for 24h. Treatment with FGIN-1-27 increased the proportion of
cells in the G0/G1 phase (black columns), whereas the proportion of cells
in the S (hatched columns) and G2/M phases (white columns) decreased.
Pretreatment with SB202190 abolished FGIN-1-27-mediated G1/S arrest.
Means of three independent experiments7s.e.m are shown.
*Po0.05,
NS¼not significant.
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PBR-ligand-mediated cell cycle arrest, we provide a link between
PBR-ligand-mediated induction of apoptosis and G1/S arrest.
Furthermore, we extend our current model on PBR-ligand-
mediated apoptosis. The signalling cascade comprises mito-
chondrial membrane permeabilisation leading to caspase-3
activation, followed by p38MAPK activation and finally DNA
fragmentation.
To clarify the PBR specificity of the effects observed, we applied
FGIN-1-52, a structural analogue of FGIN-1-27, and the benzodia-
zepine clonazepam; neither substance binding to PBR (Wang et al,
1984b; Kozikowski et al, 1993). Clonazepam or FGIN-1-52 did not
affect p38MAPK phosphorylation, gadd expression (data not
shown), apoptosis, or the cell cycle (Maaser et al, 2001; Sutter
et al, 2002). This indicates that the dose- and time-dependent
induction of the p38MAPK signalling pathway by FGIN-1-27 and
PK 11195 is PBR specific.
Protein de novo synthesis was shown to be required for PBR-
ligand-mediated induction of apoptosis (Tanimoto et al, 1999).
Therefore, we analysed the transcriptional changes in response to
treatment with FGIN-1-27. Using an apoptosis- and cell-cycle-
specific cDNA array spotted with 205 genes related to proliferation,
apoptosis and cell cycle, we have identified 78 genes, about 45
genes in either cell line, responsive to FGIN-1-27 treatment. The
fact that PBR-specific ligands exert antiproliferative effects in
different tumours (Wang et al, 1984a; Maaser et al, 2001) suggests
that PBR ligands interfere with a common signalling pathway. The
expression patterns elicited by FGIN-1-27 partially overlapped
between KYSE-140 and OE-33 cells, suggesting that those genes
commonly regulated in both cell lines are of general importance
for apoptosis and cell cycle arrest. Out of the 205 genes, only three
of those exceeding an expression ratio of 2.0 in KYSE-140 cells
were also overexpressed in OE-33 cells. Two of them were gadd45
and gadd153, both of which are known to be transcriptionally
regulated (Kultz et al, 1998). Our functional data indicate that
gadd45 and gadd153 overexpression plays an important role in
PBR-ligand-mediated apoptosis and cell cycle arrest. Many genes
were regulated by FGIN-1-27 treatment in only one of the two cell
lines. Apparently, cell-type-specific differences occur in the
signalling pathways involved in the effects of FGIN-1-27. More-
over, differences between the two cell lines may also reflect
differences in the cellular stress response to the initial stimulus.
For example, in both the cell lines we found an overexpression of
glutathione transferases in response to treatment with FGIN-1-27.
However, different isoforms of the antioxidant enzyme were
induced. In spite of the differences, the expression patterns of both
cell lines after treatment with FGIN-1-27 reflect the apoptotic and
growth-arrested phenotype of oesophageal cancer cells. In OE-33
cells, FGIN-1-27 treatment strongly decreased the expression of
survivin, which is an antiapoptotic protein with prognostic
relevance in oesophageal cancer (Grabowski et al, 2003).
Furthermore, programmed cell death 2 protein (PDCD2), a gene
associated with apoptosis of thymocytes (Kawakami et al, 1995), is
induced by FGIN-1-27. The growth arrest is reflected in the
overexpression of cdki2A and PCNA, the interaction partner of
gadd45, and the downregulation of cdc2. In KYSE-140 cells, we
observed a downregulation of cyclin C, cyclin D1 and cdc25A, all of
which are associated with G1/S transition. However, the functional
involvement of each protein has to be evaluated.
In summary, p38MAPK is dose- and time-dependently activated
by PBR-ligands. Furthermore, gadd genes are overexpressed and
apoptosis and cell cycle arrest are induced, all of which are known
consequences of p38MAPK activation. Intriguingly, all effects can
be antagonised by SB202190, which is described as a potent
p38MAPK inhibitor. Thus, our data suggest that activating the
p38MAPK pathway is a necessary step for inducing apoptosis and
cell cycle arrest by PBR-specific ligands. Understanding the
mechanisms of action will facilitate the design of combination
chemotherapies that act additively or synergistically. Furthermore,
some of the molecular targets like gadd153 and gadd45 might be
used as surrogate biomarkers for future PBR-ligand intervention
trials. Interestingly, using gadd153 induction as a predictor of
clinical response has already been evaluated for paclitaxel
treatment of cancer patients (Las Alas et al, 2000). Hence, our
data on the pathways responding to PBR-specific ligands, in
combination with the knowledge that signalling pathways may be
defective in tumours, will be helpful in predicting the responsive-
ness of tumours to PBR ligands in the future.
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